The goal of this Center for Excellence in Translational Research is to develop small molecule inhibitors of enveloped virus entry and test their efficacy in animal models of disease. The underlying hypothesis is that enveloped viral entry is replete with therapeutic targets to which small molecule inhibitors can be developed, blocking receptor engagement, membrane fusion, and cellular trafficking. Most classes of licensed antiviral drugs block intracellular steps of the replication cycle, often through interfering with virally encoded enzymes required for replication. A handful of antiviral agents block enveloped virus entry: maraviroc, a small-molecule that blocks engagement of the CCR5 co-receptor by gp 120 of human immunodeficiency virus-1; enfuvirtide, a synthetic peptide that binds gp41 of HIVI and interferes with fusion; and amantadine/rimantidine. which blocks the M2 ion channel of certain strains of influenza A virus to prevent release of the viral ribonucleoprotein segments into the cell. That paucity of synthetic entry inhibitors starkly contrasts with the natural protection mechanism of neutralizing antibodies that frequently block viral entry. This CETR will advance two general approaches to small molecule inhibition of viral entry: direct targeting of viral envelope proteins; and specific targeting of cellular factors requisite for infectious virus entry. Targeting envelope proteins has the advantage that the small molecules do not need to enter cells, thus eliminating uptake and potential export concerns, and such inhibitors may be less likely to have unwanted interactions with cellular proteins. Targeting cellular proteins offers the attractive though unproven possibility to inhibit the entry of multiple viruses with a single small molecule. A team of 6 investigators working on interdependent projects will discover and advance small molecule inhibitors of both categories.

Public Health Relevance

Both flaviviruses and filoviruses are serious pathogens with critical unmet clinical needs. Flaviviruses, including dengue virus, West Nile virus, and yellow fever virus, are widespread arthropod-transmitted human pathogens. Approximately 100 million people are infected with dengue alone each year. Although the filoviruses such as Ebola virus and Marburg virus are not as widespread as the flaviviruses, case fatality rates can approach 90%. This program seeks to identify new candidate therapeutic compounds to address these important human pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109740-02
Application #
8810214
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Maric, Maja
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
Coulter, Michael E; Dorobantu, Cristina M; Lodewijk, Gerrald A et al. (2018) The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell Rep 24:973-986.e8
Lian, Wenlong; Jang, Jaebong; Potisopon, Supanee et al. (2018) Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. ACS Infect Dis 4:1395-1406
de Wispelaere, Melissanne; Lian, Wenlong; Potisopon, Supanee et al. (2018) Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol 25:1006-1016.e8
Chao, Luke H; Jang, Jaebong; Johnson, Adam et al. (2018) How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. Elife 7:
Pitts, Jared D; Li, Pi-Chun; de Wispelaere, Melissanne et al. (2017) Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus. Antiviral Res 147:124-130
Salgado, Eric N; Upadhyayula, Srigokul; Harrison, Stephen C (2017) Single-particle detection of transcription following rotavirus entry. J Virol :
Raaben, Matthijs; Jae, Lucas T; Herbert, Andrew S et al. (2017) NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host Microbe 22:688-696.e5
Wang, May K; Lim, Sun-Young; Lee, Soo Mi et al. (2017) Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013-16 Epidemic. Cell Host Microbe 21:367-375
Filippakis, Harilaos; Alesi, Nicola; Ogorek, Barbara et al. (2017) Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R. Oncotarget 8:38099-38112
Chou, Yi-Ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-4510

Showing the most recent 10 out of 25 publications